FLT3 and acute myeloid leukemia: The selection of FLT3-mutated patients, the inhibitory effect on FLT3-TKD and the higher number of enrolled patients allowing a greater power to detect a significant difference in OS may be the most likely reasons for the significant OS benefit in the RATIFY, which lead to regulatory approval of midostaurin for use in FLT3-mutated AML.